An N-oxide where there are three organic groups bonded to the nitrogen atom.
ChEBI ID: 134363
Member | Definition | Role |
---|---|---|
(1S)-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2-methyl-2-oxido-3,4-dihydro-1H-isoquinolin-2-ium-7-ol | (1S)-1-[(3-hydroxy-4-methoxyphenyl)methyl]-6-methoxy-2-methyl-2-oxido-3,4-dihydro-1H-isoquinolin-2-ium-7-ol | |
chlorpromazine n-oxide | An organochlorine compound that is chlorpromazine in which the acyclic tertiary amino group has been converted into the corresponding N-oxide. | chlorpromazine N-oxide |
dimethylaniline n-oxide | A member of the class of dimethylanilines that is N,N-dimethylaniline in which the tertiary amino group has been oxidised to give the corresponding N-oxide. | N,N-dimethylaniline N-oxide |
dodecyldimethylamine oxide | A tertiary amine oxide resulting from the formal oxidation of the amino group of dodecyldimethylamine. | dodecyldimethylamine N-oxide |
oxymatrine | Ammothamnine | |
riddelliine n-oxide | A pyrrolizine alkaloid that is 13,19-didehydrosenecionane bearing two additional hydroxy substituents at positions 12 and 18, two additional oxo groups at positions 11 and 16 and an N-oxido substituent. | riddelliine N-oxide |
senecionine n-oxide | senecionine N-oxide | |
strychnine n-oxide | A tertiary amine oxide resulting from the oxidation of the non-acylated nitrogen of strychnine. It is a metabolite of strychnine. | strychnine N-oxide |
tamoxifen n-oxide | A tertiary amine oxide resulting from the formal oxidation of the amino group of tamoxifen. | tamoxifen N-oxide |
trimethyloxamine | A tertiary amine oxide resulting from the oxidation of the amino group of trimethylamine. | trimethylamine N-oxide |
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
---|---|---|
pre-1990 | 100 (5.65) | 18.7374 |
1990's | 136 (7.68) | 18.2507 |
2000's | 256 (14.46) | 29.6817 |
2010's | 700 (39.55) | 24.3611 |
2020's | 578 (32.66) | 2.80 |
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
---|---|---|
Trials | 75 (4.13%) | 5.53% |
Reviews | 200 (11.00%) | 6.00% |
Case Studies | 15 (0.83%) | 4.05% |
Observational | 27 (1.49%) | 0.25% |
Other | 1,501 (82.56%) | 84.16% |